{"id":261139,"date":"2022-09-02T16:36:00","date_gmt":"2022-09-02T16:36:00","guid":{"rendered":"https:\/\/sola-diagnostics.com\/?p=261139"},"modified":"2025-01-09T11:54:58","modified_gmt":"2025-01-09T10:54:58","slug":"real-life-cohort-and-validation-for-cervical-cancer","status":"publish","type":"post","link":"https:\/\/sola-diagnostics.com\/en\/real-life-cohort-and-validation-for-cervical-cancer\/","title":{"rendered":"Real-life cohort and validation for cervical cancer"},"content":{"rendered":"

[et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.0″ _module_preset=”default”][et_pb_row _builder_version=”4.27.0″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.0″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.0″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

WID-qEC test was validated in a real-life hospital cohort of 304 women.<\/strong><\/p>\n

In addition, a case-control study showed the superiority of the WID-qEC test in the detection of cervical carcinoma, especially endocervical carcinoma, compared to cytological examination.<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.0″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

Abstract<\/h2>\n
\n

The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of women suffering from vaginal bleeding actually have such a cancer. A simple, operator-independent and accurate test to correctly identify women presenting with abnormal bleeding as a consequence of endometrial or cervical cancer is urgently required. We have recently developed and validated the WID-qEC test, which assesses DNA methylation of ZSCAN12<\/i> and GYPC<\/i> via real-time PCR, to triage women with symptoms suggestive of endometrial cancer using ThinPrep-based liquid cytology samples. Here, we investigated whether the WID-qEC test can additionally identify women with cervical cancer. Moreover, we evaluate the test’s applicability in a SurePath-based hospital-cohort by comparing its ability to detect endometrial and cervical cancer to cytology. In a set of 23 cervical cancer cases and 28 matched controls the receiver operating characteristic (ROC) area under the curve (AUC) is 0.99 (95% confidence interval [CI]: 0.97-1.00) with a sensitivity and specificity of 100% and 92.9%, respectively. Amongst the hospital-cohort (n\u00a0=\u00a0330), the ROC AUC is 0.99 (95% CI: 0.98-1) with a sensitivity and specificity of 100% and 82.5% for the WID-qEC test, respectively, and 33.3% and 96.9% for cytology (considering PAP IV\/V as positive). Our data suggest that the WID-qEC test detects both endometrial and cervical cancer with high accuracy.<\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.0″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.0″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_image src=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-27-at-183457.png” _builder_version=”4.27.0″ _module_preset=”default” theme_builder_area=”post_content” title_text=”Screenshot 2024-07-27 at 183457″ url=”https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34275″ url_new_window=”on” hover_enabled=”0″ sticky_enabled=”0″][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

WID-qEC test was validated in a real-life hospital cohort of 304 women. In addition, a case-control study showed the superiority of the WID-qEC test in the detection of cervical carcinoma, especially endocervical carcinoma, compared to cytological examination.Abstract The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of […]<\/p>\n","protected":false},"author":2,"featured_media":260898,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"1500","footnotes":""},"categories":[14],"tags":[],"class_list":["post-261139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts\/261139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/comments?post=261139"}],"version-history":[{"count":0,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts\/261139\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media\/260898"}],"wp:attachment":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media?parent=261139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/categories?post=261139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/tags?post=261139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}